ClinicalTrials.gg

Colonic Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,457 studies for Colonic Neoplasms across more than 10 countries. 458 are recruiting or about to start. 1,348 of them are mainly about Colonic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Sigmoid Neoplasms too: 2,474 studies, 461 open.

ClinicalTrials.gov finds 8,370 studies for Colonic Neoplasms. How that becomes 2,456 here

This page counts the studies the registry files under Colonic Neoplasms, and those it files under no condition that list Colonic Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 8,370Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −17Filed under a narrower condition, counted on its own pageSigmoid Neoplasms 17
  3. −65List Colonic Neoplasms as a condition, but the registry did not file them under itMost often written as “Liver Metastasis Colon Cancer” (31), “Colon Cancer Screening” (6), and “Colon Cancer Liver Metastasis” (5). The registry filed them under other conditions only, most often Colorectal Neoplasms (31) and Liver Neoplasms (8).
  4. −5,832Match it another way151 name it in the title, 25 in a keyword, and 5,656 by a synonym or other text the search reads.
  5. 2,456The count on this page76 of them list Colonic Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
1,218
Status unknown
334
Recruiting
328
Terminated
221
Active, not recruiting
134
Not yet recruiting
113

Phase

Phase 2
618
Phase 1
437
Phase 3
242
Phase 4
42
Early Phase 1
26

Where

United States
1,122
France
213
China
211
Italy
135
Spain
121
Canada
115

Who develops what

Add Colonic Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 31 programs from 24 companies, 14 with this as their studies’ main aim; 8 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Pfizer, Fosun Pharma and GlaxoSmithKline here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BevacizumabRecent, repeated
Evidence
  • NCT07900165 · CytomX Therapeutics · Phase 2 · live · background · “bevacizumab + 5-FU + leucovorin” · registered Oct 2026
  • NCT07284849 · Incyte Corporation · Phase 3 · live · background · “Bevacizumab” · registered Dec 2025
  • NCT07222800 · Pfizer · Phase 3 · live · comparator · “Bevacizumab” · registered Oct 2025
  • NCT06997497 · Merck & Co., Inc · Phase 3 · live · comparator · “Bevacizumab” · registered May 2025
  • NCT05983367 · Inspirna, Inc. · Phase 2 · background · “Bevacizumab” · registered Aug 2023
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others66 studies
LeucovorinRecent, repeated
Evidence
  • NCT07900165 · CytomX Therapeutics · Phase 2 · live · background · “bevacizumab + 5-FU + leucovorin” · registered Oct 2026
  • NCT07412613 · Akeso · Phase 3 · live · comparator · “Calcium Folinate” · registered Feb 2026
  • NCT06997497 · Merck & Co., Inc · Phase 3 · live · background · “Leucovorin/levofolinate calcium” · registered May 2025
  • NCT03750786 · Isofol Medical AB · Phase 3 · comparator · “Leucovorin” · registered Nov 2018
  • NCT00862784 · Eli Lilly and Company · Phase 2 · background · “Folinic acid” · registered Mar 2009
Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed33 studies
FluorouracilRecent, repeated
Evidence
  • NCT07900165 · CytomX Therapeutics · Phase 2 · live · background · “bevacizumab + 5-FU + leucovorin” · registered Oct 2026
  • NCT07412613 · Akeso · Phase 3 · live · comparator · “5- Fluorouracil” · registered Feb 2026
  • NCT06997497 · Merck & Co., Inc · Phase 3 · live · background · “5-Fluorouracil” · registered May 2025
  • NCT02305758 · AbbVie · Phase 2 · background · “Fluorouracil infusion” · registered Dec 2014
  • NCT00862784 · Eli Lilly and Company · Phase 2 · background · “5-FU” · registered Mar 2009
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed33 studies
Folfox protocolRecent, repeated
Evidence
  • NCT07284849 · Incyte Corporation · Phase 3 · live · background · “FOLFOX” · registered Dec 2025
  • NCT05855200 · GlaxoSmithKline · Phase 3 · live · comparator · “FOLFOX” · registered May 2023
  • NCT05480306 · Leap Therapeutics, Inc. · Phase 2 · background · “FOLFOX” · registered Jul 2022
  • NCT04068610 · AstraZeneca · Phase 2 · live · background · “FOLFOX” · registered Aug 2019
  • NCT03883802 · WntResearch AB · Phase 2 · background · “FOLFOX regimen” · registered Dec 2018
Hoffmann-La Roche20% of its industry studies33 studies
CapecitabineRecent, repeated
Evidence
  • NCT07412613 · Akeso · Phase 3 · live · comparator · “Capecitabine” · registered Feb 2026
  • NCT06686576 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “CAPEOX/Capecitabine” · registered Nov 2024
  • NCT04607421 · Pfizer · Phase 3 · live · comparator · “Capecitabine” · registered Oct 2020
  • NCT00675012 · AGC Biologics S.p.A. · Phase 2 · background · “capecitabine” · registered May 2008
  • NCT00398879 · COSCIENS Biopharma Inc. · Phase 2 · background · “Capecitabine” · registered Nov 2006
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized22 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07412613 · Akeso · Phase 3 · live · comparator · “Oxaliplatin” · registered Feb 2026
  • NCT06997497 · Merck & Co., Inc · Phase 3 · live · background · “Oxaliplatin” · registered May 2025
  • NCT00862784 · Eli Lilly and Company · Phase 2 · background · “Oxaliplatin” · registered Mar 2009
  • NCT00707889 · AbbVie · Phase 2 · background · “oxaliplatin” · registered Jun 2008
  • NCT00112918 · Hoffmann-La Roche · Phase 3 · background · “Oxaliplatin” · registered Jun 2005
Sanofi35% of its industry studies22 studies
xeloxRecent, repeated
Evidence
  • NCT06686576 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “CAPEOX/Capecitabine” · registered Nov 2024
  • NCT06567782 · GlaxoSmithKline · Phase 2 · live · background · “CAPEOX” · registered Aug 2024
  • NCT05855200 · GlaxoSmithKline · Phase 3 · live · comparator · “CAPEOX” · registered May 2023
  • NCT02510118 · Nanjing NingQi Medicine Science and Technology Co., Ltd. · Phase 3 · background · “XELOX” · registered Jul 2015
AstraZeneca25% of its industry studies23 studies
CAPOX RegimenRecent, repeated
Evidence
  • NCT06686576 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “CAPEOX/Capecitabine” · registered Nov 2024
  • NCT06567782 · GlaxoSmithKline · Phase 2 · live · background · “CAPEOX” · registered Aug 2024
  • NCT05855200 · GlaxoSmithKline · Phase 3 · live · comparator · “CAPEOX” · registered May 2023
—23 studies
FOLFIRI RegimenRecent, repeated
Evidence
  • NCT05983367 · Inspirna, Inc. · Phase 2 · background · “FOLFIRI regimen” · registered Aug 2023
  • NCT05480306 · Leap Therapeutics, Inc. · Phase 2 · background · “FOLFIRI” · registered Jul 2022
  • NCT04793958 · Bristol-Myers Squibb · Phase 3 · live · comparator · “FOLFIRI Regimen” · registered Mar 2021
  • NCT00752570 · Amgen · Phase 2 · background · “FOLFIRI” · registered Sep 2008
  • NCT00454116 · Sanofi · Phase 2 · background · “FOLFIRI” · registered Mar 2007
—22 studies

12 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
RC148☆ Track1 live phase-3 study: NCT07462143RemeGen Co., Ltd.
calderasib☆ Track1 live phase-3 study: NCT06997497Merck & Co., Inc
CetuximabApproved: US 2004 · EU 2004☆ Track1 live phase-3 study: NCT06997497Merck & Co., Inc
cadonilimab☆ Track1 live phase-3 study: NCT07412613Akeso
Nuvastatic 300☆ Track1 live phase-3 study: NCT07669454Natureceuticals Sdn Bhd

The 5 in phase 3 with the nearest primary completion, of 31 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.KRAS G12D Degrader ARV-806 · Arvinas Inc. · Phase 2 registry mapping onlyNCT07023731 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation — primary endpoint: Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806 · 76 enrolled
  • 31 Mar 2027 est.Nuvastatic · Natureceuticals Sdn Bhd · Phase 3 named, not the main aimNCT07669519 Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy — primary endpoint: Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo. · 180 enrolled
  • 12 May 2027 est.RC148 · RemeGen Co., Ltd. · Phase 3 main aimNCT07462143 A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer — primary endpoint: Objective Response Rate (ORR) · 80 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Colonic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 43 open · Antimetabolites 7 open · Tyrosine kinase inhibitors (TKIs) 6 open · Angiogenesis inhibitors 5 open · Alkylating agents 2 open

Coming up

149studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger. 19 (6%) take children under 18. 3 (1%) are for women only and 0 (0%) for men only; 35 (11%) take healthy volunteers.

Recruiting studies that take each age, of 328
AgeWomenMen
1013 (4%)13 (4%)
18291 (89%)289 (88%)
30305 (93%)303 (92%)
40309 (94%)307 (94%)
50315 (96%)313 (95%)
65316 (96%)314 (96%)
75309 (94%)307 (94%)
85238 (73%)238 (73%)

Across all 2,457 studies, recruiting or not: 17% stop at 75 or younger and 3% at 65; 8% take children; 1% are for women only and <1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Colonic Neoplasms studies take

Of 136 phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 148 mo32–69 · 116 studies54 mo30–64 · 51 studies46 mo32–69 · 65 studies
Phase 1/265 mo40–93 · 59 studies——
Phase 243 mo30–66 · 136 studies—43 mo29–66 · 123 studies
Phase 355 mo37–119 · 72 studies—87 mo39–123 · 55 studies
Phase 429 mo20–105 · 16 studies——
Interventional, no phase30 mo16–51 · 404 studies—31 mo17–55 · 382 studies
Observational50 mo27–116 · 225 studies—54 mo24–116 · 186 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Stopped1

Studies

Recruiting first, then most recently updated. Showing 50 of 2,457. Browse all 2,457 → or search them.